Cardiol Therapeutics Inc Class A (TO:CRDL) — Market Cap & Net Worth
Market Cap & Net Worth: Cardiol Therapeutics Inc Class A (CRDL)
Cardiol Therapeutics Inc Class A (TO:CRDL) has a market capitalization of $138.15 Million (CA$190.97 Million) as of October 14, 2026. Listed on the TO stock exchange, this Canada-based company holds position #17979 globally and #582 in its home market, demonstrating a -15.76% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Cardiol Therapeutics Inc Class A's stock price CA$1.71 by its total outstanding shares 111680087 (111.68 Million).
Cardiol Therapeutics Inc Class A Market Cap History: 2018 to 2026
Cardiol Therapeutics Inc Class A's market capitalization history from 2018 to 2026. Data shows change from $359.51 Million to $138.15 Million (-10.72% CAGR). Check CRDL share price today for real-time trading data and today's change.
Cardiol Therapeutics Inc Class A Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Cardiol Therapeutics Inc Class A's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Also see CRDL cash flow conversion for how efficiently the company converts equity into cash flow.
Latest Price to Sales (P/S) Ratio
2389.99x
Cardiol Therapeutics Inc Class A's market cap is 2389.99 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $224.59 Million | $78.76K | -$20.65 Million | 2851.57x | N/A |
| 2021 | $188.24 Million | $78.76K | -$24.72 Million | 2389.99x | N/A |
Competitor Companies of CRDL by Market Capitalization
Companies near Cardiol Therapeutics Inc Class A in the global market cap rankings as of October 14, 2026. See CRDL net asset quality score to understand what proportion of total assets are financed by equity.
Key companies related to Cardiol Therapeutics Inc Class A by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #528 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #580 globally with a market cap of $46.89 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #627 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #643 globally with a market cap of $42.48 Billion USD ( CN¥290.31 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #528 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #580 | GALDERMA GROUP AG | NYSE:GALDY | $46.89 Billion | $40.22 |
| #627 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €16.50 |
| #643 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $42.48 Billion | CN¥45.51 |
Cardiol Therapeutics Inc Class A Historical Marketcap From 2018 to 2026
Between 2018 and today, Cardiol Therapeutics Inc Class A's market cap moved from $359.51 Million to $ 138.15 Million, with a yearly change of -10.72%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CA$138.15 Million | +30.53% |
| 2025 | CA$105.83 Million | -29.19% |
| 2024 | CA$149.46 Million | +68.18% |
| 2023 | CA$88.87 Million | +59.42% |
| 2022 | CA$55.74 Million | -70.39% |
| 2021 | CA$188.24 Million | -16.19% |
| 2020 | CA$224.59 Million | -39.30% |
| 2019 | CA$370.01 Million | +2.92% |
| 2018 | CA$359.51 Million | -- |
End of Day Market Cap According to Different Sources
On Oct 14th, 2026 the market cap of Cardiol Therapeutics Inc Class A was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $138.15 Million USD |
| MoneyControl | $138.15 Million USD |
| MarketWatch | $138.15 Million USD |
| marketcap.company | $138.15 Million USD |
| Reuters | $138.15 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Cardiol Therapeutics Inc Class A
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for… Read more